These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18799917)

  • 21. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.
    Baek JH; Kim H; Ahn JJ; Jegal Y; Seo KW; Ra SW; Park CR; Jung JP; Kim JW; Lee YJ; Cha HJ; Kwon WJ; Noh YJ; Oh S; Park JH; Min YJ
    Lung Cancer; 2012 Jun; 76(3):368-72. PubMed ID: 22192919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient].
    Fujimoto H; Oyama T; Suito T; Hashimoto K; Kameyama Y; Yasuda H; Ishizuka H
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):295-8. PubMed ID: 20154488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [An elderly case of recurrent colon cancer responding to weekly S-1 chemotherapy leading to partial response].
    Arita A; Sakai Y; Fujimoto M; Mochizuki K
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):141-3. PubMed ID: 18195545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer.
    Kobayashi S; Ueno M; Sugimori K; Morizane C; Kojima Y; Irie K; Goda Y; Morimoto M; Ohkawa S
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1189-1196. PubMed ID: 29071413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
    Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
    Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Three cases of long-term control of non-small-cell lung cancer via S-1 monotherapy in elderly patients].
    Numata T; Osawa H; Homma Y; Yanai H; Endo T
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):379-82. PubMed ID: 25812513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
    Satouchi M; Kotani Y; Katakami N; Shimada T; Urata Y; Yoshimura S; Funada Y; Hata A; Ando M; Negoro S
    J Thorac Oncol; 2010 May; 5(5):696-701. PubMed ID: 20147856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
    Takiguchi Y; Seto T; Ichinose Y; Nogami N; Shinkai T; Okamoto H; Minato K; Seki N; Eguchi K; Kishi K; Nishikawa M; Watanabe K
    J Thorac Oncol; 2011 Jan; 6(1):156-60. PubMed ID: 21107293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer].
    Miyagawa K; Yata Y; Yamaoka N; Sagara Y
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1145-7. PubMed ID: 20567125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case report of S-1 single effective use as third-line chemotherapy and re-challenge in a recurrent squamous cell lung cancer patient].
    Hoshino S; Sugano T; Kitamura T; Furukawa M; Aragane K
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1181-4. PubMed ID: 18633258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of pancreatic acinar cell carcinoma with a giant liver metastasis successfully treated with combination of gemcitabine and peroral S-1].
    Nishimizu T; Minemura M; Kajiura S; Tokimitsu Y; Itaya Y; Yamawaki H; Kawai K; Tajiri K; Nakayama Y; Hosokawa A; Takahara T; Yasumura S; Shimizu S; Fukuoka J; Ishizawa S; Sawasaki T; Yanagisawa A; Sugiyama T
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):309-12. PubMed ID: 21368502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
    Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
    Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The progress of chemotherapy for advanced pancreatic cancer].
    Ioka T; Katayama K; Ashida R; Takahashi H; Teshima T; Sakon M
    Nihon Shokakibyo Gakkai Zasshi; 2015 Dec; 112(12):2119-26. PubMed ID: 26638783
    [No Abstract]   [Full Text] [Related]  

  • 36. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
    Huang PW; Chang CF; Hung CY; Hsueh SW; Chang PH; Yeh KY; Chen JS; Chen YY; Lu CH; Hung YS; Chou WC
    Cancer Med; 2019 Sep; 8(12):5554-5563. PubMed ID: 31385456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
    Takashima A; Morizane C; Ishii H; Nakamura K; Fukuda H; Okusaka T; Furuse J
    Jpn J Clin Oncol; 2010 Dec; 40(12):1189-91. PubMed ID: 20630899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [S-1+gemcitabine (GEM) therapy effective in a case of pancreatic body cancer with multiple liver metastasis].
    Fukui H; Kou C; Matsumoto T; Matsumoto M
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1775-8. PubMed ID: 20841945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
    Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
    Jpn J Clin Oncol; 2021 Apr; 51(4):604-611. PubMed ID: 33479765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effective combination chemotherapy with gemcitabine hydrochloride, S-1 and nedaplatin for recurrent pancreatic cancer--a case report].
    Tokairin Y; Iida M; Yamazaki S
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2123-5. PubMed ID: 19106544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.